Intravenous Cardioversion of Atrial Fibrillation (AF) With AZD1305

Phase 2 Completed 228 enrolled AstraZeneca

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being carried out to see which dose of AZD1305 is safe and effective in cardioverting atrial fibrillation into normal heart rhythm.

Timeline

Start: 2009-05
Primary completion: 2009-12
Completion: 2009-12

Outcome

Met primary endpoint

paper 8 of 45 (18%; P= 0.006), 17 of 45 (38%; P< 0.001), and 6 of 12 patients (50%; P< 0.001) in AZD1305 dose groups 1-4, respectively. PMID 21561900 ↗

paper CONCLUSIONS: AZD1305 was effective in converting AF to SR PMID 21561900 ↗

Publications

Ronaszeki A, Alings M, Egstrup K, Gaciong Z, Hranai M, Kiraly C, Sereg M, Figatowski W, Bondarov P, Johansson S, Frison L, Edvardsson N, Berggren A. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously. Europace. 2011 Aug;13(8):1148-56. doi: 10.1093/europace/eur120. Epub 2011 May 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1305	Small molecule	50 mg	Intravenous
Subject	AZD1305	Small molecule	100 mg	Intravenous
Subject	AZD1305	Small molecule	130 mg	Intravenous
Subject	AZD1305	Small molecule	180 mg	Intravenous